Innoviva, Inc. (THRX)
Feb 14, 2024 - THRX was delisted (reason: acquired by Concentra Biosciences)
4.060
0.00 (0.00%)
Inactive · Last trade price on Feb 13, 2024

Theseus Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1,1451,0861,0289251,1991,256
Market Cap Growth
-5.66%11.18%-22.87%-4.58%-12.40%
Enterprise Value
1,2531,3471,3671,1671,5451,210
PE Ratio
48.9546.435.724.324.515.60
PS Ratio
3.193.033.312.793.063.73
PB Ratio
1.661.571.521.632.282.07
P/TBV Ratio
2.462.342.413.232.892.33
P/FCF Ratio
6.085.767.314.593.304.01
P/OCF Ratio
6.075.767.294.583.304.01
EV/Sales Ratio
3.493.764.403.523.943.59
EV/EBITDA Ratio
6.036.528.395.244.123.75
EV/EBIT Ratio
6.947.469.695.384.123.75
EV/FCF Ratio
6.657.159.725.794.253.87
Debt / Equity Ratio
0.750.750.771.090.750.63
Debt / EBITDA Ratio
2.502.503.152.741.051.19
Debt / FCF Ratio
2.762.763.693.051.091.23
Asset Turnover
0.280.280.250.310.410.39
Inventory Turnover
0.980.981.02---
Quick Ratio
2.112.117.282.6353.7755.72
Current Ratio
2.352.359.033.2954.0255.98
Return on Equity (ROE)
3.43%3.43%28.97%40.35%65.06%61.86%
Return on Assets (ROA)
8.88%8.88%7.12%12.57%24.34%23.40%
Return on Invested Capital (ROIC)
9.39%9.39%7.43%12.91%24.50%23.56%
Return on Capital Employed (ROCE)
17.00%17.00%11.70%19.80%40.70%32.50%
Earnings Yield
2.04%2.15%17.48%23.14%22.18%17.86%
FCF Yield
16.46%17.35%13.68%21.81%30.35%24.92%
Buyback Yield / Dilution
-14.61%8.79%-1.00%16.95%-0.13%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q